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Abstract
Doxorubicin (Adriamycin) is an effective anti-cancer drug, but its clinical usage is limited by a dose-dependent cardiotoxicity
characterized by widespread sarcomere disarray and loss of myofilaments. Cardiac ankyrin repeat protein (CARP, ANKRD1) is
a transcriptional regulatory protein that is extremely susceptible to doxorubicin; however, the mechanism(s) of doxorubicin-
induced CARP depletion and its specific role in cardiomyocytes have not been completely defined. We report that
doxorubicin treatment in cardiomyocytes resulted in inhibition of CARP transcription, depletion of CARP protein levels,
inhibition of myofilament gene transcription, and marked sarcomere disarray. Knockdown of CARP with small interfering
RNA (siRNA) similarly inhibited myofilament gene transcription and disrupted cardiomyocyte sarcomere structure.
Adenoviral overexpression of CARP, however, was unable to rescue the doxorubicin-induced sarcomere disarray phenotype.
Doxorubicin also induced depletion of the cardiac transcription factor GATA4 in cardiomyocytes. CARP expression is
regulated in part by GATA4, prompting us to examine the relationship between GATA4 and CARP in cardiomyocytes. We
show in co-transfection experiments that GATA4 operates upstream of CARP by activating the proximal CARP promoter.
GATA4-siRNA knockdown in cardiomyocytes inhibited CARP expression and myofilament gene transcription, and induced
extensive sarcomere disarray. Adenoviral overexpression of GATA4 (AdV-GATA4) in cardiomyocytes prior to doxorubicin
exposure maintained GATA4 levels, modestly restored CARP levels, and attenuated sarcomere disarray. Interestingly, siRNA-
mediated depletion of CARP completely abolished the Adv-GATA4 rescue of the doxorubicin-induced sarcomere
phenotype. These data demonstrate co-dependent roles for GATA4 and CARP in regulating sarcomere gene expression and
maintaining sarcomeric organization in cardiomyocytes in culture. The data further suggests that concurrent depletion of
GATA4 and CARP in cardiomyocytes by doxorubicin contributes in large part to myofibrillar disarray and the overall
pathophysiology of anthracycline cardiomyopathy.
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Introduction
Adriamycin (doxorubicin) is an effective anti-cancer drug,
whose use is limited by the development of a dose-dependent
cardiomyopathy and congestive heart failure. Cardiac tissue
from animals and patients treated with doxorubicin are
histologically characterized by swelling of the sarcoplasmic
reticulum and mitochondria, cytoplasmic vacuolization, and
widespread loss and disarray of sarcomeres (for reviews see [1,2]).
Cardiac sarcomeres are highly organized structures and maintain
a strict stoichiometry of myofilament proteins allowing efficient
generation of contractile force [3]. Myofilament stoichiometry, in
turn, relies on the coordinated turnover of myofilament proteins
that efficiently replaces worn out or damaged myofilament
proteins. This equilibrium is presumably regulated by sarcomeric
elements able to mechanically ‘‘sense’’ myofilament protein
deficits and signals the cardiomyocyte to induce myofilament
gene transcription.
Cardiac ankyrin repeat protein (CARP, a.k.a. cardiac adriamy-
cin responsive protein and ANKRD1) is a member of a family of
conserved muscle ankyrin repeat proteins (MARPS) that include
ankrd2 and diabetes ankyrin repeat protein (DARP) [4,5,6].
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35743CARP was originally discovered as the nuclear protein C-193 [7]
but later independently characterized by Zou et al. as a co-factor
for transcription factor YB-1 and by Jeyaseelan et al. as a gene
whose mRNA was ‘‘exquisitely sensitive’’ to doxorubicin treatment
[8,9]. Due to its association with the transcriptional repressor YB-
1, CARP was originally thought to act as a suppressor of cardiac
genes, including myosin light chain 2v (MLC-2v), atrial natriuretic
factor (ANF), and cardiac troponin C (cTnC). In three distinct
models of cardiac hypertrophy in rats (constriction of abdominal
aorta; spontaneously hypertensive; Dahl salt-sensitive) Aihara et al.
found increased CARP expression [10]. In addition to YB1,
CARP has been shown to interact with sarcomeric proteins:
myopalladin, desmin, muscle specific RING finger proteins
(MuRFs), the N2A portion of titin, cardiac calsequestrin and
CARP itself [11,12,13,14]. In cardiomyocytes in culture, CARP
has been shown to be essential for sarcomere organization through
its interaction with the sarcomere protein myopalladin [11].
Recently, several missense mutations in the CARP gene,
ANKRD1, were identified in patients with dilated and hypertro-
phic cardiomyopathy [15,16], and in vitro studies of these
mutations suggest disruption of CARP localization and cardiac
stretch-based signaling. Given its dual subcellular localization,
within the nucleus and sarcomere, it has been proposed that
Figure 1. Sarcomeric and nuclear localization of CARP in ARVMs. A: Low magnification (406) images of ARVMs co-stained with antibodies to
CARP (green) and myomesin (red). B: High magnification (1006) of ARVMs immunostained for CARP (green) and myomesin (red, left image) or a-
actinin (red, right image), and shown below the image is the corresponding fluorescence intensity along the white arrow in the red and green
channels.
doi:10.1371/journal.pone.0035743.g001
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relaying a muscle stretch signal to induce gene expression [6,17].
GATA4 (a member of the GATA family of zinc finger
transcription factors) is expressed in the adult heart and is
important in regulating cardiac hypertrophy and cardiomyocyte
survival [18]. Previous studies in cardiomyocytes have shown that
doxorubicin depletes GATA4 levels and induces apoptosis and
that restoration of GATA4 levels by adenovirus mediated gene
transfer is able to prevent the doxorubicin-induced autophagy and
apoptosis [19,20,21]. Interestingly, CARP has been shown to be a
downstream target of GATA4 [22,23]. Thus GATA4 and CARP
could be part of a signaling pathway that is important for
sarcomere organization and cardiomyocyte survival.
In this study we explored a possible link between the disruption
of GATA4/CARP signaling and doxorubicin-induced sarcomere
disarray in rat cardiomyocytes. Our results demonstrate that both
CARP and GATA4 maintain sarcomere integrity by regulating
myofilament gene transcription, and that loss of either CARP or
GATA4 in vitro directly contributes to myofibrillar disarray. These
observations offer insight into the role of GATA4 and CARP in
sarcomere homeostasis and may lead to novel therapeutic
strategies that can treat or limit the debilitating effects of
doxorubicin cardiomyopathy.
Materials and Methods
Ethics Statement
This study was carried out in accordance with the recommen-
dations of the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. The protocols for all
experiments using vertebrate animals were approved by the
Institutional Animal Care and Use Committee at Vanderbilt
University Medical Center.
Primary Isolation of Cardiac Myocytes and Cell Culture
Adult rat ventricular myocytes (ARVMs) were isolated from
male Sprague-Dawley rats (,200 g), plated on laminin-coated
culture dishes and cultured, as previously described [24]. Culture
medium contained Dulbecco’s modified Eagle’s medium (DMEM,
Invitrogen) supplemented with 7% fetal bovine serum (FBS,
Invitrogen), 2 mg/mL albumin (Sigma), 5 mM creatine (Sigma),
2 mM L-carnitine (Sigma), 5 mM taurine (Sigma), 1% 100 units/
ml penicillin/streptomycin (Invitrogen), and 100 mM bromode-
oxyuridine (BrdU, Sigma). Culture media was changed 1 h after
plating and every two days until the day of the experiment.
Myocytes were treated on day 9 or 10 in culture with: doxorubicin
(Sigma), N-acetyl-L-leucyl-norleucinal (ALLN, Sigma), cyclohex-
imide (Sigma), actinomycin D (Sigma) at concentrations and time-
points indicated elsewhere.
Figure 2. Doxorubicin decreases CARP levels in ARVMs. A: ARVMs were treated for 24 h with increasing concentrations of doxorubicin and
cell lysates analyzed by immunoblot for CARP and actin. Also shown is a time course of CARP and tubulin expression in ARVMs treated with 1 mM
doxorubicin. CARP densitometry values for the time-course were normalized to tubulin and expressed as a percentage of the 0 time-point. Shown are
mean6SD from 4 independent experiments. * P,0.05 relative to 0 time-point. B: Cells were harvested and fractionated at various time points into
nuclear and cytoplasmic extracts and analyzed for CARP expression by immunoblot. CARP densitometry values were normalized to tubulin
(cytoplasmic fraction) or topoisomerase (nuclear fraction) and expressed as a percentage of the 0 time-point.
doi:10.1371/journal.pone.0035743.g002
Role of GATA4/CARP in Doxorubicin Cardiomyopathy
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35743Neonatal rat ventricular myocytes (NRVMs) were isolated from
hearts of 2-day old Sprague-Dawley rat pups as previously
described [24], and cells were cultured in DMEM supplemented
with 7% FBS. NRVMs were cultured overnight in low serum
media (1% FBS/DMEM) prior to plasmid transfection, adenoviral
infection at a multiplicity of infection of 100 (MOI 100), and/or
chemical treatment.
Quantitative Real-Time RT-PCR
Total RNA from isolated ARVMs was extracted using TRIzol
reagent (Invitrogen) using standard methods. One step quantita-
tive real-time RT-PCR was performed using the QuantiTect
SYBR Green kit from Qiagen with a Cepheid SmartCycler.
Primers were designed to a region of the rat CARP gene sequence
spanning exons 3–5 (forward: 59-GAAGGAACCGGAGCCTGA-
39; reverse: 59-CACGATCGCC AAGTGTCC-39). Samples were
normalized by real-time RT-PCR with an internal control using
primers targeting the 18S ribosome protein L32 (forward 59-
ACTGGAATTCGCTGCCCTCCGGCCT-39; reverse: 59-GCA-
TAAGCTTTCGGTCTGA CTGGTG-39. Standard curves were
generated to determine the linear range and efficiency for each
primer set. Experiments were repeated in triplicate and CT values
were measured 5 times per individual sample. The high and low
values were removed and the remaining 3 were averaged.
Constructs and siRNAs
We generated promoter reporter constructs by cloning from
mouse cDNA a putative CARP promoter region (2660 to 0 bp)
and from human cDNA the cardiac alpha actin promoter region
(2557 to 0 bp) and titin promoter region (2548 to 0 bp) into the
pGL3 luciferase reporter plasmid (Promega). The FLAG-tagged
GATA4 expression vector was a kind gift from Dr. Mona Nemer.
An adenovirus containing full-length mouse CARP cDNA was
generated as previously described [25]. We obtained a truncated
N-terminal epitope of myomesin fused to GFP (kind gift from Dr.
Jeane-Claude Perriard) and cloned it into a tet-regulatable
adenoviral construct. The CMV-EGFP adenovirus (Cell Biolabs,
Inc) and the CMV-GATA4 adenovirus (Seven Hills Bioreagents)
were purchased. All adenoviruses were amplified and purified to
high titer (Virabind, Cell Biolabs, Inc).
Short interfering RNA (siRNA) were designed and synthesized
against exon 4 of the rat CARP sequence (NM_0.1220.1, CARP-
siRNA: 59-GAACCGGAGCCTGAAATTATT-39), rat GATA4
sequence (NM_144730, predesigned siRNA from Qiagen), and
Figure 3. Calpain inhibition preserves sarcomere structure but not CARP levels in ARVMs treated with doxorubicin. A:
Immunofluorescent images of untreated ARVMs (a–c) or ARVMs treated for 24 h with 1 mM doxorubicin (Doxo, d–f) in the presence or absence of
100 mM N-acetyl-L-leucyl-norleucinal (ALLN, g–i). ARVMs were co-stained for CARP (green) and myomesin (red); arrowheads indicate presence of
dense myomesin aggregates.
doi:10.1371/journal.pone.0035743.g003
Role of GATA4/CARP in Doxorubicin Cardiomyopathy
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35743siRNA non-silencing control (59-AATTCTCCGAACGTGT-
CACGT-39). Lipofectamine 2000 (Invitrogen) and siRNA were
diluted with Opti-MEM (Invitrogen) and the mixture was
subsequently transfected into ARVMs or NRVMs. After 4 h, the
media was changed to DMEM supplemented with 7% FBS,
penicillin-streptomycin and BrdU under normal growth condi-
tions. Cells were lysed for analysis up to 96 h after transfection.
Gel electrophoresis and immunoblotting
Cells were lysed in modified RIPA buffer: 10% NP-40, 0.5 M
EDTA, 0.5 M Tris-HCl (pH 7.4), 5 M NaCl, 1 M NaF, protease
inhibitor cocktail (P8340, Sigma) and PMSF (1:100). The samples
were centrifuged at 14,000 rpm at 4uC to pellet out cellular debris.
The supernatant was measured for protein concentration using
the Bio-Rad RC/DC protein assay. Cell lysates were subse-
quently boiled in Laemmli sample buffer, loaded, and separated
on 12% Tris-HCl polyacrylamide gels (Cambrex). The gel was
transferred to PVDF membranes (Amersham Biosciences) for
immunoblotting.
The affinity purified CARP polyclonal rabbit antibody was
produced from a peptide encoded by an N-terminal 300-bp
fragment of CARP cDNA (bases 31–349), as previously described
[25]. Membrane blots were incubated with antibodies to either
CARP (diluted in 5% BSA/0.1% TBST), GATA4 (Santa Cruz
Biotech, clone G4, sc-25310) total actin (Sigma, A-3853, clone
AC-40) or a-tubulin (Santa Cruz Biotech, sc-5286, clone B-7)
o v e r n i g h ta t4 uC, followed by anti-rabbit or anti-mouse IgG
conjugated to HRP (Santa Cruz Biotech,) for 1 h at room
temperature. All primary antibodies were used at 1:1,000
dilution and secondary antibody at 1:5,000. Reactive bands
were detected on film by chemiluminescence (Pierce Chemical
Co.), scanned, and band densities were quantitated using ImageJ
(NIH) software.
For titin analysis, cells were lysed in a modified Laemmli buffer
according to Warren et al. [26], with the addition of protease
inhibitors (0.04 mM Leupeptin, 0.01 mM E-64, and 0.5 mM
PMSF). Samples were heated at 60uC and immediately loaded on
1% agarose gels. Gels were fixed and following Coomassie
staining, wet-scanned at 400 dpi.
Immunofluorescence
Cardiomyocytes were fixed with 4% paraformaldehyde/PBS
for 30 minutes, and permeabilized with 0.2% Triton-X/PBS at
30 minutes, as previously described [24]. Samples were incubated
with primary antibodies to myomesin (B4, University of Iowa
Hybridoma Bank), a-actinin (Santa Cruz Biotech), or CARP,
followed by incubation with fluorophore-conjugated secondary
antibodies (Alexa dyes, Invitrogen) and Texas-Red phalloidin (for
staining filamentous actin). The cells were mounted on a coverslip
using VectaShield (Vector Labs) mounting media and sarcomere
morphology was analyzed using an inverted fluorescence confocal
microscope (LSM 510, Zeiss). To quantify myofibrillar damage,
myocytes were score based on .50% disruption of myomesin
striations, accumulation of dense myomesin aggregates, or
reduction in actin staining as previously described [24]. For each
condition in each experiment, a total of 100–150 cardiomyocytes
were counted by an experimenter blinded to the experiment.
Myomesin-GFP Transfection and Time-lapse
Fluorescence Microscopy
ARVMs were infected with myomesin-GFP and Tet-off
adenoviral vectors at an MOI of 1 and at ratio of 1:1. Cells were
incubated for approximately 24 h at which time myomesin-GFP
fluorescence was visible. The media was replaced with phenol-free
media and the fluorescent cells were transfected with CARP
siRNA-325 or non-silencing siRNA and allowed to incubate up to
4 days.
Time-lapse microscopy was conducted using an Olympus IX81
inverted fluorescent microscope outfitted with a PrecisionControl
WeatherStation chamber for maintaining CO2, temperature and
humidity levels. Cells were subjected to time-lapse (Slidebook
software, Intelligent Imaging Innovations, Denver, CO) and
images were recorded on a single field excited at 489 nm at 1,
4, and 6 days.
Figure 4. Calpain inhibition preserves titin but not CARP levels.
ARVMs were treated for 24 h with 1 mM doxorubicin and cell lysates
analyzed for A: titin in Coomassie stained agarose gels (representative
of 4 independent experiments, arrowheads indicate titin degradation
product), and B: CARP and tubulin by immunoblot. C: Bar graph shows
corresponding quantification of CARP immunoblot analysis (% of
control, n=3) and myofibrillar disarray (% of cells scored for .50%
disruption of myomesin striations as described in Methods, n=4–5,
,150 cells counted per experiment). Shown are mean6SD, P,0.05
relative to control (*) and Doxo ({).
doi:10.1371/journal.pone.0035743.g004
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The luciferase-reporter transfections were carried out in
NRVMs cultured on 24-well plates at 70–80% confluence using
Lipofectamine 2000 (Invitrogen) following manufacturer’s instruc-
tions. NRVMs were transfected with 200 ng of the promoter
luciferase construct for 24 h. Transfection efficiency was moni-
tored by co-transfecting NRVMs with 200 ng pRL-TK vector
(Promega) that contains the renilla luciferase gene. Firefly and
renilla luciferase activities were determined by a GloMax-Multi
Detection system (Promega). The ratio of firefly:renilla luciferase
activities was calculated to normalize for differences in cell number
and transfection efficiency. Each experiment was run in triplicate
and the ratio value was determined for each construct to allow for
between-experiment comparison.
Statistical Analysis
Data are reported as mean6SD. Where appropriate, results
were either analyzed by Student’s t-test or ANOVA with a
Bonferroni’s multiple comparison post-hoc test. P,0.05 was
considered statistically significant.
Results
CARP expression and localization in Adult Rat Ventricular
Myocytes (ARVM)
We used the primary dedifferentiated adult rat ventricular
cardiomyocyte (ARVM) model and were able to confirm CARP
mRNA and protein expression in these cells (supplemental,
Figure S1). Immunostaining of CARP in paraformaldehyde-
fixed ARVMs showed a striated sarcomeric pattern with intense
staining in the nucleus (Figure 1A). Confocal images taken from
ARVMs co-immunostained with CARP and either a-actinin (Z-
line protein) or myomesin (M-line protein) revealed CARP
staining adjacent to the Z-line (Figure 1B, Figure S2), which
corresponds to CARP localization at the I-band. This is in
agreement with previous studies in mouse ventricular tissue and
neonatal rat and embryonic chick cardiomyocytes, showing that
CARP localized in the nucleus and at the N2A region of titin in
the I-band [6,11].
CARP is susceptible to doxorubicin treatment
To determine the susceptibility of CARP to doxorubicin,
ARVMs were incubated at different concentrations of doxorubicin
for 24 h and CARP levels analyzed by immunoblot. Our data
show that CARP is extremely sensitive to doxorubicin when
compared to actin; as little as 0.5 mM doxorubicin was sufficient to
suppress CARP protein expression and a time course of ARVMs
treated with 1 mM doxorubicin showed a significant decrease in
CARP levels as early as 3 h to less than 20% of control by 24 h
(Figure 2A). The immunoblot data were corroborated by
immunofluorescent images of ARVMs treated for 24 h with
1 mM doxorubicin, with immunostaining of sarcomeric and
nuclear CARP often appearing diffuse and less intense compared
to control cells (Figure 3). Since CARP resides in both the
cytoplasm and nucleus of cardiomyocytes, we examined the
relative susceptibility of CARP to doxorubicin in both compart-
ments. Interestingly, there was a decrease in cytoplasmic CARP
concomitant with a transient increase in nuclear CARP followed
Figure 5. Doxorubicin inhibits CARP expression at the transcriptional level. A: ARVMs were pretreated with 10 mg/ml cycloheximide
(Cyclo), a protein synthesis inhibitor, in the presence or absence of 1 mM doxorubicin (Doxo) and cell lysates analyzed by immunoblot for CARP and
actin and corresponding densitometry analysis is shown below. B: Comparison of CARP mRNA decay (quantified by RT-PCR) in ARVMs pretreated
with 5 mg/ml actinomycin D (act D) in the presence or absence of 1 mM doxorubicin. C: NRVMs were transfected with a CARP promoter luciferase
reporter (CARP-pGL3) and treated with increasing concentrations of doxorubicin. Cell lysates were assayed for luciferase activity and values were
normalized to a promoterless control (pGL3 basic). Shown are mean6SD from 4 independent experiments. The qRT-PCR and luciferase-reporter
experiments were performed in triplicate. * P,0.05, ANOVA.
doi:10.1371/journal.pone.0035743.g005
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35743Figure 6. CARP siRNA knockdown in ARVMs. A: ARVMs were transfected for 24 h with increasing concentrations of CARP targeted siRNA and
lysates analyzed by immunoblot for CARP and tubulin. Also shown is a time course of CARP and tubulin levels in ARVMs transfected with 50 nM
CARP- siRNA. B: Cells were harvested at various time-points and fractionated into nuclear and cytoplasmic extracts and analyzed for CARP expression
by immunoblot. CARP densitometry values were normalized to tubulin or topoisomerase and expressed as a percentage of the 0 time-point.
doi:10.1371/journal.pone.0035743.g006
Figure 7. CARP knockdown in ARVMs induces sarcomere disarray. A: ARVMs were transfected with 50 nM nonsilencing siRNA (top panel) or
50 nM CARP-siRNA (bottom panel and fixed at 48 h for immunofluorescence imaging. Cells were stained for CARP (green) myomesin (blue), and
filamentous actin (red).
doi:10.1371/journal.pone.0035743.g007
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This was confirmed by immunostaining of CARP in doxorubicin
treated ARVMs, which showed increased staining of nuclear
CARP at 6 and 12 h followed by an overall decrease in CARP
immunostaining at later time-points (Figure S3).
Calpain inhibition prevents myofibrillar disarray and
preserves titin but not CARP levels
We have previously shown that doxorubicin induces titin
degradation in ARVMs and that co-treatment with N-acetyl-L-
leucyl-norleucinal (ALLN), an inhibitor of the calcium-dependent
calpain proteases, was able to preserve titin levels and prevent
myofibrillar disarray [24]. Given that CARP interacts with I-band
titin, it is also possible that calpain-induced proteolysis of titin
releases bound CARP, making it more susceptible to degradation.
Thus, we determined whether preservation of titin levels by
calpain inhibition during doxorubicin treatment could also
stabilize and preserve CARP levels. We examined the effects of
doxorubicin on titin by agarose gel electrophoresis and sarcomere
structure by evaluation of the immunostaining pattern of
myomesin [24,27]. ARVMs treated with 1 mM doxorubicin for
24 h showed partial degradation of titin (Figure 4A) as previously
reported [24,27], decreased CARP levels, and significant myofi-
brillar disarray with dense aggregation and reduced staining of
myomesin (Figures 3, 4B, and 4C). Pretreating ARVMs with
100 mM ALLN prior to doxorubicin preserved titin levels and
almost completely restored myomesin staining, but ALLN did not
restore either CARP protein levels or its staining pattern
(Figures 3 and 4).
These data suggest that CARP degradation is not mediated by
the calpains and that preservation of titin and/or myofilament
structure during doxorubicin treatment does not preserve
sarcomeric localization or the stability of CARP. Hence titin
degradation is not a prerequisite for doxorubicin-induced
degradation of CARP.
Doxorubicin suppresses CARP through a transcriptional
mechanism
Since doxorubicin-induced CARP reduction was calpain-
independent, we examined whether doxorubicin enhanced
degradation of CARP protein by any other proteolytic system.
ARVMs were pretreated with 10 mg/ml cycloheximide, a protein
biosynthesis inhibitor, for 1 h prior to treatment with 1 mM
doxorubicin (the control group was treated only with cyclohexi-
mide). ARVMs were harvested over various time-points to
compare the rate of CARP degradation between the two groups.
Western blot analysis showed no significant difference in the rate
of CARP degradation between cycloheximide alone and in
combination with doxorubicin (Figure 5A). Similarly, we wanted
to ascertain whether doxorubicin inhibits CARP transcription or
destabilizes CARP mRNA. ARVMs were pretreated for 1 h with
5 mg/ml actinomycin D, a transcriptional inhibitor, prior to
treatment with 1 mM doxorubicin, and cells were lysed over
various time points for total RNA extraction. We also treated cells
individually with either actinomycin D or with doxorubicin. By
quantitative RT-PCR analysis, ARVMs treated with doxorubicin
alone showed a rapid decline in CARP mRNA, whereas untreated
control demonstrated stable levels of CARP mRNA (Figure 5B).
However, ARVMs treated with actinomycin D alone versus
actinomycin D with doxorubicin had an equivalent rate of CARP
mRNA reduction, suggesting that CARP mRNA degradation is
not enhanced with doxorubicin.
To confirm that doxorubicin inhibits CARP at the transcrip-
tional level, neonatal rat ventricular myocytes (NRVM) were
transfected with a CARP promoter-luciferase reporter (CARP-
pGL3) and treated with different concentrations of doxorubicin.
The CARP promoter was strongly activated under basal
conditions (,300 fold) in NRVMs; doxorubicin induced a dose-
dependent decrease, with complete suppression of CARP
promoter activity at 0.5 and 1.0 mM doxorubicin (Figure 5C).
These findings suggest that the decrease in CARP expression
during doxorubicin treatment was neither due to enhanced CARP
protein degradation nor destabilization of mRNA transcripts, but
rather due to suppression of CARP mRNA transcription.
CARP siRNA induces myofibrillar disarray
Doxorubicin has well-known pleiotropic effects. To better
define the consequences of CARP inhibition alone, we utilized
siRNA to specifically knockdown CARP levels. CARP-siRNA
suppressed CARP mRNA transcripts by over 75% compared to a
non-silencing siRNA transfected control. A dose response and
time-course revealed almost complete suppression of CARP
protein by 48 h in ARVMs treated with 50 nM CARP siRNA
(Figure 6A). CARP-siRNA had no effect on GATA4 and
phospho-ERK1/2 levels suggesting no or minimal off-target
effects (data not shown). Immunofluorescence studies revealed
that ARVMs transfected with 50 nM CARP siRNA for 48 h had
Figure 8. Preservation of CARP in NRVM does not rescue
doxorubicin-induced sarcomere disarray. A: NRVMs were treated
for 24 h with increasing concentrations of doxorubicin and cell lysates
analyzed by immunoblot for CARP, GATA4, and tubulin. B: NRVMs were
treated with 0.5 mM doxorubicin alone or infected with adenoviral CARP
(AdV-CARP) for 24 h followed by doxorubicin treatment for 24 h and
cell lysates were analyzed by immunoblot for CARP and tubulin. C:
Immunofluorescent images of untreated control, NRVMs treated with
0.5 mM doxorubicin alone or NRVM infected with AdV-CARP for 24 h
followed by doxorubicin for 24 h. NRVMs were co-stained for myomesin
(green) and filamentous actin (red). Note: the purple appearance of
nuclei is due to the overlay of DAPI staining with red autofluorescence
from doxorubicin intercalated into nuclear DNA.
doi:10.1371/journal.pone.0035743.g008
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some retention in the nuclei, and this was accompanied by drastic
decreases in filamentous actin and myomesin striations within the
cell (Figure 7). Quantification of myofibrillar damage showed a
significant increase in sarcomere disarray in CARP-siRNA treated
ARVMs (55.0610.6% vs. 6.860.6%, n=3, ,150 cells counted
per experiment, * P,0.05 relative to control). Analysis of the effect
of CARP siRNA on the cytoplasmic and nuclear CARP
compartments revealed similar dynamics in CARP distribution
as seen with doxorubicin, however, the transient increase in
nuclear CARP occurred much later in CARP-siRNA compared to
doxorubicin treated cells (compare Figures 2B and 6B, and
Figure S3).
To visualize sarcomere changes due to CARP silencing in real-
time, ARVMs were infected with an adenovirus expressing a
truncated myomesin-GFP (which localizes to the M-line). After
24 h cells were treated with CARP-siRNA and changes in
myomesin-GFP were tracked using time-lapse fluorescence
microscopy. Sarcomeric M-line striations were visible 24 h after
infection and would persist at 4 days in untreated and non-
silencing siRNA controls (Figure S4). CARP suppression resulted
in a gradual loss of M-line striations by day 2 along with
accumulation of densely fluorescent intracellular aggregates. Thus,
targeted suppression of CARP recapitulates the doxorubicin-
induced sarcomeric injury phenotype.
CARP overexpression does not rescue doxorubicin-
induced sarcomere disarray
Since CARP-siRNA knockdown in cardiomyocytes induces a
similar sarcomere disarray phenotype as seen with doxorubicin,
we sought to determine if CARP overexpression can rescue
doxorubicin-induced sarcomere disarray. We used adenovirus-
mediated gene transfer to overexpress CARP (AdV-CARP) in
cardiomyocytes. NRVMs treated with 0.1 or 0.5 mM doxorubicin
for 24 h resulted in marked depletion of CARP (Figure 8A).
NRVMs pre-infected with AdV-CARP for 24 h followed by 0.1 or
0.5 mM doxorubicin maintained their CARP similar to control
levels (Figure 8B). However, this preservation of CARP failed to
rescue the doxorubicin-induced sarcomere disarray phenotype, as
shown by the aberrant M-line immunostaining (Figure 8C);
quantification of sarcomere disarray (Dox=69.965.7%, vs.
Dox+AdV-CARP=66.568.0%, n=4, ,150 cells counted per
experiment, P=NS). Thus, CARP depletion alone does not
account for the doxorubicin-induced sarcomere disarray pheno-
type.
GATA4 is an upstream regulator of CARP
Previous studies have shown that doxorubicin suppresses the
transcription factor GATA4 and that GATA4 regulates CARP
expression [20,22,23]. We confirmed that 24 h of doxorubicin
treatment in NRVMs resulted in depleted GATA4 levels
(Figure 8A). Moreover, transient cotransfection experiments in
HEK-293 cells showed a dose-dependent increase in CARP
promoter activity with increasing concentrations of GATA4
expression vector (Figure 9A). There was endogenous activation
of the CARP promoter in the absence of GATA4 expression
vector, however, we were unable to detect GATA4 by western blot
in HEK-293 cells. To further examine the role of GATA4 and
CARP we performed cotransfection experiments in cardiomyo-
cytes. Knockdown of GATA4 by siRNA markedly suppressed
CARP promoter activity (Figure 9B) and CARP protein levels
(24 h=55613%, 48 h=25617% vs. nonsilencing control;
P,0.05, Figure 9C) and induced extensive cardiomyocyte
sarcomere disarray (Figure 9D). Interestingly, CARP promoter
Figure 9. GATA4 is an upstream regulator of CARP. A: HEK-293 cells were cotransfected with CARP-pGL3 promoter (filled bars) and increasing
concentrations of GATA4 expression plasmids and cell lysates were assayed for luciferase activity. The experiment was repeated with a promoterless
pGL3 vector (open bars) as control. B: NRVMs were transfected with CARP-pGL3 along with either GATA4-siRNA, CARP-siRNA, or AdV-CARP for 24 h
and cell lysates were assayed for luciferase activity. All luciferase-reporter experiments were performed in triplicate. Values were normalized to
untreated pGL3 basic and shown as mean6SD from 4 independent experiments. C: Representative CARP immunoblot of NRVMs transfected with
nonsilencing control or GATA4-siRNA for 24 or 48 h. D: Representative immunofluorescent images of NRVMs transfected with nonsilencing control or
GATA4-siRNA for 48 h. NRVMs were co-stained for myomesin (green), filamentous actin (red), and DAPI (blue).
doi:10.1371/journal.pone.0035743.g009
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suggesting an autoregulatory negative feedback mechanism for
CARP in cardiomyocytes. Given that both CARP- and GATA4-
siRNA induce sarcomere disarray, we examined whether GATA4
and CARP regulate sarcomere gene transcription. Cotransfection
of either a titin promoter reporter or actin promoter reporter with
either 0.5 mM doxorubicin, CARP-siRNA, or GATA4-siRNA
showed significant decreases in promoter activity (Figure 10).
Thus, GATA4 regulates CARP expression and works with
CARP to co-regulate sarcomere gene expression.
GATA4 overexpression modestly restores CARP and
partially rescues the doxorubicin-induced sarcomere
disarray
Since GATA4 and CARP regulate sarcomere gene expression
and GATA4 is upstream of CARP, we examined whether GATA4
overexpression could rescue the doxorobucin-induced sarcomere
disarray phenotype. NRVMs treated with 0.5 mM doxorubicin
showed significant depletion of GATA4 and CARP levels
(Figures 11A and B). When infected with AdV-GATA4 for
24 h prior to doxorubicin, GATA4 levels were increased and
CARP levels were modestly but significantly higher when
compared to doxorubicin treatment alone. Overexpression of
GATA4 attenuated the doxorubicin-induced sarcomere disarray
as evidenced by preservation of striated M-line immunostaining
(Figures 11C and D). Having modest levels of CARP with
GATA4 overexpression appears to be critical as depletion of CARP
by siRNA cotransfection abolished the AdV-GATA4 rescue effect
in doxorubicin treated cells, resulting in complete sarcomere
disarray in almost all cells examined (Figures 11B and D). Thus,
GATA4 overexpression can partially rescue the doxorubicin–
induced sarcomere disarray phenotype, and both GATA4 and
CARP are required for maintaining cardiac sarcomeres.
Discussion
Even though CARP was first identified as an exquisitely
sensitive target of doxorubicin [8], studies examining the
relationship between CARP and doxorubicin cardiotoxicity have
been scant. In the present work we show that doxorubicin depletes
both GATA4 and CARP levels in cultured cardiomyocytes, and
that GATA4 overexpression (but not CARP overexpression) was
able to attenuate doxorubicin-induced sarcomere disarray. We
demonstrate that GATA4 directly regulates CARP and that the
protective effect of GATA4 was mediated in part by modulating
CARP expression and downstream sarcomere genes. These results
are the first to identify CARP as a mediator for GATA4 in a
signaling axis that converges to control sarcomere gene expression
and maintain organized sarcomeres.
Doxorubicin induces sarcomere disarray and a rapid decrease
in CARP protein levels in both ARVM and NRVM, with the
phenotype appearing to be more severe in NRVM. CARP is
believed to be a ‘‘hot spot’’, titin-based, mechanosensory unit as it
interacts with the elastic N2A domain of titin (for reviews see
[28,29]). Consistent with our previous report, doxorubicin induced
titin degradation in ARVMs and co-treatment with a calpain
inhibitor restored titin levels and preserved myofibrillar structure
[24]. However, calpain inhibition did not preserve CARP levels
suggesting that 1) CARP is not a calpain substrate and 2) the
susceptibility of CARP to doxorubicin is independent of a
preserved titin and/or sarcomere structure. The latter might be
explained by impaired CARP binding to N2A titin, perhaps due to
post-translational modifications, leading to enhanced degradation
of free CARP by some other proteolytic mechanism. However, in
this study ARVMs treated with cycloheximide in the presence or
absence of doxorubicin showed no difference in the rate of CARP
loss, thus arguing against accelerated CARP degradation; instead
we were able to demonstrate that doxorubicin induced transcrip-
tional inhibition of CARP. Support for this comes from a previous
study showing doxorubicin-induced suppression of CARP tran-
scription via activation of a H7-sensitive serine/threonine kinase
pathway [30].
Neonatal cardiomyocytes subjected to stretch accumulate
CARP in the sarcomeric I-band as well as in the nucleus,
suggesting that CARP might couple mechanical strain to muscle
gene transcription [6]. Following doxorubicin exposure, we also
observed a transient sarcomeric to nuclear translocation of CARP.
We speculate that in response to doxorubicin-induced mechanical
perturbation (titin degradation) sarcomeric CARP localizes to the
nucleus to modulate myofilament gene transcription; this gene
transcription ultimately ceases as total CARP levels are eventually
depleted with doxorubicin. It is unclear how CARP regulates
cardiac gene expression, but CARP is known to be a transcrip-
tional co-factor and has been shown to interact in vitro with
multiple transcription factors involved in cardiac gene expression,
including YB-1, HAND2, and HEY1 [9,31].
The cardiac transcription factor GATA4 plays a pivotal role in
cardiomyocyte hypertrophy and survival and it has been
implicated in sarcomere gene transcription and regulation of the
Figure 10. CARP and GATA4 regulate titin and actin transcrip-
tion. NRVMs were cotransfected with either a titin promoter reporter
(A) or actin promoter (B) along with 0.5 mM doxorubicin, CARP-siRNA,
or GATA4-siRNA. Luciferase-reporter experiments were performed in
triplicate. Values were normalized to untreated pGL3 basic and shown
as mean6SD from 4 independent experiments.
doi:10.1371/journal.pone.0035743.g010
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likely mediated by different downstream effectors, which remain
poorly defined. GATA4 is known to be sensitive to doxorubicin
[19,20,22,23]. Here we show that selective siRNA knockdown of
GATA4 suppressed CARP promoter activity, depleted CARP
protein levels, and induced extensive cardiomyocyte sarcomere
disarray. These findings suggest that doxorubicin-induced deple-
tion of GATA4 is directly responsible for loss of CARP, and they
implicate CARP as a downstream mediator of GATA4 in
regulating sarcomere maintenance. Overexpression of GATA4
enhanced CARP promoter activity in HEK293 cells whereas
GATA4 siRNA knockdown in cardiomyocytes resulted in
suppression of CARP promoter activity, confirming that GATA4
directly regulates CARP. CARP siRNA knockdown induced
marked cardiomyocyte sarcomere disarray as seen with GATA4
siRNA, and either CARP or GATA4 siRNA resulted in significant
Figure 11. GATA4 overexpression in NRVM results in partial rescue of doxorubicin-induced sarcomere disarray. A: Representative
immunoblots for CARP and GATA4 from NRVMs infected with AdV-GATA4 and treated with doxorubicin in the presence or absence of CARP-siRNA. B:
Corresponding densitometry values normalized to control are shown for CARP (open bars) and GATA4 (filled bars). Shown are mean6SD, n=6,
P,0.05 relative to control (*), Doxo only (1), and Doxo+AdV-GATA4 ({) C: Immunofluorescent images of NRVMs treated with 0.5 mM doxorubicin
alone or infected with AdV-GATA4 for 24 h followed by doxorubicin for 24 h. NRVMs were stained for myomesin (green), filamentous actin (red), and
DAPI (blue). D: Bar graph shows % sarcomere disarray (n=5–8, ,150 cells counted per experiment). Values shown as mean6SD, P,0.05 relative to
control (*) and Doxo only treatment (1).
doi:10.1371/journal.pone.0035743.g011
Figure 12. Cardiac sarcomere structure is maintained by a balance between sarcomere protein synthesis and degradation. We
postulate that GATA4 regulates CARP expression and both act to induce sarcomere gene transcription. CARP expression is subject to a negative
feedback regulatory mechanism. GATA4 siRNA and CARP siRNA both inhibit CARP signaling and sarcomere gene expression, resulting in an
imbalance in protein turnover and eventual sarcomere disruption. Doxorubicin (actions marked by red x in figure) exacerbates sarcomere disruption
by downregulation of GATA4 and CARP, degrading key sarcomeric proteins (e.g. titin), and inhibiting new sarcomere protein synthesis via
transcriptional/translational impairment.
doi:10.1371/journal.pone.0035743.g012
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actin. Overexpression of CARP failed to rescue the doxorubicin-
induced sarcomere disarray phenotype, which was not unexpected
as the concomitant loss of GATA4 is predicted to inhibit other
downstream pathways distinct from sarcomeric organization such
as survival pathways [19]. Furthermore, CARP is hypothesized to
be a mechanosensor linking changes in titin mechanical strain to
gene transcription, and it is unclear how overexpression of ectopic
CARP might affect this endogenous mechanosensing or transcrip-
tional activity of CARP. It is interesting that CARP promoter
activity was inversely related to CARP expression, suggesting a
negative feedback mechanism to strictly control CARP levels in
cardiomyocytes. As previously noted, CARP is a cofactor for
multiple cardiac transcription factors and stringent regulation of
CARP is perhaps necessary to limit an exaggerated hypertrophic
response. Future studies are needed to examine the role of CARP
in cardiac hypertrophy.
Overexpression of GATA4, on the other hand, markedly
attenuated doxorubicin-induced cardiomyocyte sarcomere disar-
ray. This finding is consistent with previous studies which showed
that GATA4 overexpression protects against cardiomyocyte
apoptosis and autophagy due to doxorubicin toxicity [19,20,21].
These previous studies indicated that GATA4 upregulates
antiapoptotic factors Bcl-X and Bcl2, and Bcl2 in turn suppresses
autophagy-related genes [19,21]. Interestingly, GATA4 overex-
pression modestly, but significantly, increased CARP levels in
doxorubicin treated cardiomyocytes. Our finding that knockdown
of this modest increase in CARP completely abrogated the rescue
of GATA4 overexpression in doxorubicin treated cells suggest that
CARP and GATA4 are both essential in maintaining organized
sarcomeres. Our finding that CARP plays a central role in
sarcomere maintenance in cultured cardiomyocytes, appears to
contradict a study by Barash et al. which showed a relatively mild
skeletal muscle phenotype in a triple KO mouse model of the
MARP genes (including CARP), with no overt cardiac phenotype
reported [17,33]. One possible explanation is that other titin-based
mechanosensors can compensate for the lack of CARP in vivo, e.g
the MLP/telethonin/N-titin, MURF2/titin kinase, or FHL1/
N2B-titin complexes [34,35,36]. The possibility that CARP is
dispensable for basal in vivo cardiac function but is important under
conditions of stress, such as pressure overload or myocardial
infarction, requires further investigation. We also cannot rule out
the possibility that when cultured in vitro, cardiomyocytes remodel
and adapt to the rigid two-dimensional environment, where
CARP becomes absolutely essential for sarcomere integrity.
GATA4 and thecardiac-enriched transcriptionfactorNkx2.5are
known mutual co-activators [37], and a previous study has shown
that Nkx2.5 and GATA4 cooperatively regulate CARP expression
[22,37]. The GATA4/Nkx2.5 interaction has been shown to
mediate a mechanical stretch-activated hypertrophic program in
cardiomyocytes that enhances sarcomere assembly and organiza-
tion [38]. We speculate that Nkx2.5, GATA4, and CARP all
converge on a final common signaling pathway to regulate
sarcomere gene transcription and sarcomere maintenance, and
that loss of any one of these factors results in cardiomyocyte
sarcomere disarray. We further speculate that cardiomyocyte
mechanical stretch targets this same Nkx2.5/GATA4/CARP
signaling pathway to induce cardiomyocyte hypertrophy and
enhance sarcomere organization and assembly. A recent study
showed that Ankrd2, another member of the MARP family of
proteins enriched in skeletal muscle, interacts with transcriptional
regulators and structural and signaling proteins to affect a multitude
of pathways including myogenesis, gene expression, as well as intra-
and intercellular signaling [39]. We anticipate that future studies on
CARP will uncover novel signaling pathways and processes with
important regulatory functions in the heart.
The mechanisms of anthracycline cardiotoxicity are diverse and
include 1) oxidative stress and membrane lipid damage, 2) calcium
overload, and 3) inhibition of protein transcription and translation
(reviewed in [40,41]). These conditions collectively lead to
myofibrillar disarray, where acceleration of myofilament protein
degradation and simultaneous repression of muscle gene expres-
sion leads to a net negative balance of sarcomeric proteins. In this
paradigm, the downregulation of GATA4 and CARP contributes
in part to this phenotype by preventing synthesis of sarcomere
proteins and sarcomere assembly (Figure 12). The hypothesis that
CARP/N2A-titin make up a stretch-sensing unit that intersects
with Nkx2.5/GATA4 signaling is particularly attractive as a
mechanism for cardiomyocytes to rapidly adjust sarcomere
homeostasis to the changing physiological demands of the heart.
Supporting Information
Figure S1 CARP expression in Adult Rat Ventricular
Myocyte (ARVM). A: Total mRNA was isolated from ARVM
and CARP expression was detected by RT-PCR using primers
that targeted a 197 bp portion of CARP cDNA. RT-PCR was
performed at various RNA concentrations and PCR products
were run on 10% agarose gel and visualized with ethidium
bromide. B: Total protein was extracted from ARVM and lysates
were subjected to western blot using purified anti-CARP antibody.
(TIF)
Figure S2 High magnification images of a-actinin (red)
and CARP (green) and shown below is the corresponding
fluorescence intensity along the white arrows in the
images. The dashed lines in the histograms are aligned with a
peak in each channel, indicating labeling of CARP on either side
of the Z-line.
(TIF)
Figure S3 ARVMs were treated with 1 mM doxorubicin
or transfected with 50 nM CARP siRNA at various time
points. Cells were fixed and immunostained for CARP (green)
and myomesin (blue).
(TIF)
Figure S4 Time-lapse fluorescence microscopy of CARP
siRNA induced myofibrillar disarray. ARVMs were
infected for 24 hours with an adenoviral construct containing a
truncated N-terminal epitope of myomesin fused to GFP which
localizes to the M-line. Following M-line fluorescence expression,
time-lapse microscopy was performed on ARVMs that were
untreated (A, B, C), treated with nonsilencing siRNA (D, E, F), or
transfected with CARP siRNA (G, H, I). Images were taken at 0,
2, and 4 days (d0, d2, d4) for untreated and nonsilencing siRNA,
and at 0, 1, and 2 days (d0, d1, d2) for CARP siRNA.
(TIF)
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